Investigators seeking to order CJC-1295 No DAC online for laboratory research require verifiable chemical identity, ultra-high purity, and strict lot consistency. CJC-1295 No DAC (Modified GRF 1-29) is a synthetic 29-amino acid GHRH analog engineered to stimulate physiological, pulsatile growth hormone secretion. Sourcing through PX1 Research ensures US-manufactured, >98% HPLC-purified material backed by lot-specific COAs and same-day dispatch.
Investigators seeking to order CJC-1295 No DAC online for laboratory research require verifiable chemical identity, ultra-high purity, and strict lot consistency. CJC-1295 No DAC (Modified GRF 1-29) is a synthetic 29-amino acid GHRH analog engineered to stimulate physiological, pulsatile growth hormone secretion. Sourcing through PX1 Research ensures US-manufactured, >98% HPLC-purified material backed by lot-specific COAs and same-day dispatch.
When procurement officers and laboratory investigators prepare to order CJC-1295 No DAC online, establishing stringent verification criteria is critical to protecting experimental integrity. CJC-1295 without DAC—chemically designated as Modified GRF 1-29—is a tetrasubstituted peptide derived from human growth hormone-releasing hormone (GHRH). Unlike its long-acting conjugated counterpart, CJC-1295 No DAC retains a shorter biological half-life, allowing researchers to study physiological, pulsatile growth hormone (GH) secretion dynamics in controlled bioassays.
To maintain valid experimental controls, researchers must source research peptides from vendors that supply comprehensive documentation. Substandard synthetic peptides frequently present structural truncated sequences, residual trifluoroacetic acid (TFA), or endotoxin contamination, all of which can alter cellular signaling in cell cultures or animal models. PX1 Research provides fully transparent, lot-specific analytical data accessible via our centralized research library, ensuring every vial meets exact chemical specifications.
CJC-1295 No DAC is a 29-amino acid peptide analog corresponding to the active N-terminal domain of endogenous GHRH (1-44). In its natural state, wild-type GHRH 1-29 (Sermorelin) is rapidly degraded in systemic circulation by the enzyme dipeptidyl peptidase IV (DPP-IV), which cleaves the peptide between positions Ala2 and Asp3 within minutes.
To enhance metabolic stability without altering receptor binding mechanics, peptide chemists introduced four specific amino acid substitutions at critical positions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These modification sites significantly increase resistance to enzymatic cleavage while preserving full agonistic activity at the GHRH receptor (GHRH-R). Preclinical studies suggest that this altered primary sequence stabilizes the alpha-helical conformation required for optimal receptor engagement.
The primary mechanism of CJC-1295 No DAC involves high-affinity binding to the GHRH receptor, a Class B G-protein coupled receptor located on somatotroph cells within the anterior pituitary gland. Upon ligand binding, GHRH-R undergoes a conformational change that stimulates heterotrimeric G-protein signaling, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA).
This signaling cascade opens voltage-gated calcium channels, triggering the exocytosis of pre-stored growth hormone vesicles into the pericapillary space. Because CJC-1295 No DAC lacks the Maleimidopropionic acid (DAC) linker that binds serum albumin, it is rapidly cleared via renal filtration and local proteolysis. In vitro assays and rodent models demonstrate that this rapid clearance profile causes short, acute bursts of GH release that closely mimic natural physiological secretion, rather than continuous non-pulsatile secretion.
In preclinical animal models, CJC-1295 No DAC has been extensively utilized to investigate cellular repair pathways, nitrogen retention, and metabolic regulation. Following GHRH receptor activation, elevated GH levels stimulate hepatic synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1), as well as localized tissue IGF-1 expression.
Preclinical data indicate that pulsatile GH surges play a regulatory role in osteoblast differentiation, chondrocyte proliferation, and skeletal muscle satellite cell activation. Research focused on muscle tissue repair indicates that downstream IGF-1 upregulation activates the Akt/mTOR signaling pathway, promoting protein synthesis and inhibiting myostatin expression. Because CJC-1295 No DAC does not produce continuous pituitary stimulation, receptor downregulation and somatotroph desensitization are minimized in short-duration testing protocols.
Understanding where CJC-1295 No DAC fits within the broader landscape of growth hormone secretagogues requires evaluating peptide kinetics, half-life, and receptor selectivity. Researchers frequently compare Modified GRF 1-29 against related analogs to select the appropriate compound for specific protocol objectives.
When comparing CJC-1295 No DAC to CJC-1295 DAC, the primary differentiator is the inclusion of the Drug Affinity Complex. CJC-1295 DAC covalently binds to circulating serum albumin, extending its biological half-life to several days and driving continuous, non-pulsatile GH release. Conversely, CJC-1295 No DAC exhibits a half-life of approximately 30 minutes in rodent models, delivering sharp, discrete GH spikes. When compared to Sermorelin, Modified GRF 1-29 demonstrates superior enzymatic stability due to its four structural substitutions. Furthermore, researchers frequently co-administer GHRH analogs with selective ghrelin receptor agonists like Ipamorelin in preclinical models, as dual pathway activation yields a synergistic release of GH without disrupting cortisol or prolactin homeostasis. For broader comparative data, visit our guide on growth hormone secretagogues.
PX1 Research enforces strict quality control standards to ensure that every lot of CJC-1295 No DAC delivered to research facilities meets analytical grade purity. Every batch undergoes rigorous testing in an ISO 17025 accredited laboratory prior to distribution.
Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) is performed to determine chemical purity, confirming a threshold of ≥98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) verifies exact molecular mass (3367.9 Da) and amino acid sequence fidelity, ruling out truncated peptides or incorrect peptide synthesis. Additionally, because bacterial endotoxins can confound immunological and cellular research outcomes, all lots undergo Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly under <0.1 EU/mg.
To preserve structural integrity during laboratory handling, CJC-1295 No DAC must be reconstituted using standardized laboratory aseptic techniques. Lyophilized peptide cakes should be allowed to equilibrate to room temperature before adding liquid diluent to prevent condensation from destabilizing the peptide matrix.
Researchers typically reconstitute CJC-1295 No DAC using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution for immediate in vitro application. The diluent should be aimed down the glass wall of the vial rather than sprayed directly onto the lyophilized powder. Gentle swirling is recommended to complete dissolution; mechanical agitation, vigorous shaking, or sonication must be strictly avoided as shear forces can disrupt the alpha-helical secondary structure. For precise diluent calculations, consult our online peptide reconstitution calculator.
Peptides in lyophilized format exhibit high thermal stability when stored under appropriate environmental conditions. Unopened vials of CJC-1295 No DAC should be preserved at -20°C in a desiccated environment, where they remain stable for up to 24 months. For short-term transit, room-temperature exposure during shipping does not compromise peptide stability.
Once reconstituted into aqueous solution, the peptide becomes susceptible to hydrolytic oxidation and enzymatic breakdown. Reconstituted CJC-1295 No DAC solutions should be maintained at 2°C to 8°C and evaluated within 14 to 21 days. Multiple freeze-thaw cycles must be avoided, as phase changes cause mechanical stress that promotes peptide aggregation and denaturation.
Sourcing research compounds from overseas or unverified suppliers introduces significant risk, including variable purity, improper storage conditions during international transit, and lack of lot traceability. PX1 Research eliminates supply chain ambiguity by maintaining domestic, cGMP-compliant manufacturing and distribution infrastructure.
All research peptides offered by PX1 Research are synthesized in the United States, packaged in climate-controlled facilities, and dispatched directly from our California and Arizona fulfillment centers. Institutions establishing recurring orders or volume procurement contracts can explore our wholesale options to streamline acquisition while securing verified lot consistency.
What is the primary difference between CJC-1295 No DAC and CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex linker, resulting in a short half-life (~30 minutes) and producing pulsatile growth hormone release. CJC-1295 with DAC binds to serum albumin, extending its half-life to several days and causing continuous GH elevation.
What purity level is guaranteed when ordering CJC-1295 No DAC from PX1 Research?
PX1 Research guarantees a minimum purity threshold of ≥98.0% for every lot of CJC-1295 No DAC, as verified by independent RP-HPLC analysis.
Is CJC-1295 No DAC intended for human therapeutic use or clinical administration?
No. CJC-1295 No DAC is supplied strictly as a research compound for laboratory, in vitro, and preclinical animal investigation. It is not approved for human consumption, therapeutic use, or clinical administration.
What documentation accompanies CJC-1295 No DAC orders?
Each batch is accompanied by a lot-specific Certificate of Analysis (COA) containing RP-HPLC purity chromatograms, Mass Spectrometry structural identity confirmation, and LAL endotoxin testing results.
How should lyophilized CJC-1295 No DAC be stored upon receipt?
Lyophilized CJC-1295 No DAC should be stored in a freezer at -20°C in a dry, dark environment to preserve long-term stability.
What diluent is recommended for reconstituting CJC-1295 No DAC in research setups?
Sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) is standard for multi-use research protocols, while sterile 0.9% Sodium Chloride is frequently used for immediate, single-use in vitro assays.
What are the acceptable endotoxin limits for PX1 Research peptides?
All research peptides, including CJC-1295 No DAC, are tested via LAL assay to ensure endotoxin levels remain below <0.1 EU/mg, preventing unspecific immune responses in experimental models.
Where does PX1 Research ship CJC-1295 No DAC from?
All orders are fulfilled directly from PX1 Research warehouse facilities located in California and Arizona, offering same-day dispatch for orders placed Monday through Friday before cut-off times.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.